We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
-11.51%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$101M
AUM Growth
-$17.5M
(-15%)
Cap. Flow
-$4.67M
Cap. Flow
% of AUM
-4.63%
Top 10 Holdings %
Top 10 Hldgs %
44.39%
Holding
99
New
23
Increased
11
Reduced
26
Closed
11
Avg Time Held
3.2
quarters
Top 10 Avg Time Held
3.3
quarters
Top 20 Avg Time Held
3.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adverum Biotechnologies
ADVM
|
+$1.8M |
| 2 |
ESSA Pharma
EPIX
|
+$1.59M |
| 3 |
NEOS
Neos Therapeutics, Inc
NEOS
|
+$1.4M |
| 4 |
Windtree Therapeutics Inc
WINT
|
+$1.28M |
| 5 |
Abeona Therapeutics
ABEO
|
+$965K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$2.03M |
| 2 |
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
|
+$1.66M |
| 3 |
AtriCure
ATRC
|
+$1.52M |
| 4 |
Dermira, Inc.
DERM
|
+$832K |
| 5 |
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
|
+$812K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.83% |
| 2 | Miscellaneous | 15.67% |
| 3 | Technology | 0.3% |
| 4 | Financials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
AtriCure
ATRC
$2.89B
| $10.7M | 10.61% |
487,946
-60,665
| -11% | -$1.52M |
2013 Q2
9 quarters
|
|
2
AbbVie
ABBV
$485B
| $6.34M | 6.29% |
116,581
| – | – |
2015 Q2
1 quarter
|
|
|
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
| $5.78M | 5.74% |
366,554
| – | – |
2013 Q2
9 quarters
|
|
|
ZSPH
4
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $4.35M | 4.31% |
66,194
-906
| -1% | -$54.4K |
2015 Q1
2 quarters
|
|
|
ACHN
5
DELISTED
Achillion Pharmaceuticals
ACHN
| $3.32M | 3.29% |
480,300
| – | – |
2014 Q3
4 quarters
|
|
6
BioCryst Pharmaceuticals
BCRX
$2.06B
| $2.95M | 2.93% |
258,642
+36,986
| +17% | +$494K |
2014 Q3
4 quarters
|
|
|
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
| $2.94M | 2.92% |
165,669
+8,827
| +6% | +$160K |
2014 Q3
4 quarters
|
|
8
DELISTED
BioTelemetry, Inc.
BEAT
| $2.88M | 2.86% |
235,645
| – | – |
2013 Q2
9 quarters
|
|
9
Insulet
PODD
$9.58B
| $2.75M | 2.73% |
106,018
| – | – |
2013 Q2
9 quarters
|
|
10
Rigel Pharmaceuticals
RIGL
$881M
| $2.74M | 2.72% |
110,974
| – | – |
2014 Q4
3 quarters
|
|
|
11
DELISTED
Windtree Therapeutics Inc
WINT
| $2.25M | 2.24% |
536,325
+193,834
| +57% | +$1.28M |
2013 Q2
9 quarters
|
|
|
AGTC
12
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $2.07M | 2.05% |
157,192
| – | – |
2015 Q1
2 quarters
|
|
|
OTIC
13
DELISTED
Otonomy, Inc.
OTIC
| $1.99M | 1.97% |
111,466
| – | – |
2015 Q1
2 quarters
|
|
14
DELISTED
Masimo
MASI
| $1.77M | 1.76% |
46,010
| – | – |
2013 Q2
9 quarters
|
|
|
DSCI
15
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $1.68M | 1.67% |
356,918
-17,000
| -5% | -$110K |
2013 Q2
9 quarters
|
|
|
XNPT
16
DELISTED
XENOPORT, INC.
XNPT
| $1.63M | 1.62% |
470,612
-60,420
| -11% | -$381K |
2013 Q2
9 quarters
|
|
|
SGYP
17
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $1.57M | 1.56% |
296,563
-21,000
| -7% | -$163K |
2015 Q2
1 quarter
|
|
|
18
DELISTED
ESSA Pharma
EPIX
| $1.42M | 1.41% |
+11,425
| New | +$1.59M |
2015 Q3
0 quarters
|
|
19
Protalix BioTherapeutics
PLX
$222M
| $1.41M | 1.4% |
119,319
-3,760
| -3% | -$59.8K |
2013 Q2
9 quarters
|
|
|
CYTR
20
DELISTED
CytRx Corp
CYTR
| $1.38M | 1.37% |
97,169
+47,033
| +94% | +$797K |
2014 Q1
6 quarters
|
|
21
Tvardi Therapeutics
TVRD
$13.9M
| $1.34M | 1.33% |
2,599
-928
| -26% | -$621K |
2015 Q2
1 quarter
|
|
|
NEOS
22
DELISTED
Neos Therapeutics, Inc
NEOS
| $1.33M | 1.32% |
+63,400
| New | +$1.4M |
2015 Q3
0 quarters
|
|
23
Stereotaxis
STXS
$106M
| $1.27M | 1.26% |
1,372,862
-343,216
| -20% | -$340K |
2013 Q2
9 quarters
|
|
|
CYAD
24
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
| $1.26M | 1.25% |
30,000
| – | – |
2015 Q2
1 quarter
|
|
|
25
DELISTED
Adverum Biotechnologies
ADVM
| $1.16M | 1.15% |
+14,060
| New | +$1.8M |
2015 Q3
0 quarters
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, DAFNA Capital Management held 99 positions worth $101M, down 15% from $118M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
DAFNA Capital Management withdrew a net $4.67M in Q3 2015, closing 11 positions and reducing 26 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $2.03M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, DAFNA Capital Management opened a new position in Adverum Biotechnologies worth $1.16M.
- DAFNA Capital Management's largest Q3 2015 buy was Adverum Biotechnologies: 14,060 shares worth $1.16M.
- DAFNA Capital Management added most to Windtree Therapeutics Inc in Q3 2015, an estimated $1.28M increase.
- DAFNA Capital Management's biggest Q3 2015 reduction was AtriCure, cutting an estimated $1.52M.
- DAFNA Capital Management fully exited Clovis Oncology, Inc. in Q3 2015, selling an estimated $2.03M.
- DAFNA Capital Management's ten largest holdings make up 44% of its $101M portfolio in Q3 2015.
- DAFNA Capital Management opened 23 new positions and closed 11 in Q3 2015.
- DAFNA Capital Management's portfolio value fell 15% quarter-over-quarter to $101M.
Based on DAFNA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.